Floatz logo

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)

Pulmonary Inflammation

Synspira, Inc.OtherPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Pulmonary Inflammation cohort.

Asset / SponsorPhaseRating
Amifostine
MedImmune LLC
Phase 2B
Tocilizumab
National Cancer Institute (NCI)
Phase 2CCC
HUMAN IMMUNOGLOBULINS
ECOG-ACRIN Cancer Research Group
Phase 2CCC
Infliximab
ECOG-ACRIN Cancer Research Group
Phase 2CCC
PREDNISONE TABLETS
ECOG-ACRIN Cancer Research Group
Phase 2CCC

View all 11 →

Same molecule, other indications

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW) is also rated in:

burkholderia infectious diseaseDormant
CC
Indicative ·
43 / 100
View asset →
respiratory system disorderDormant
CC
Indicative ·
43 / 100
View asset →
Lung InflammationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →